A Digital Solution for an Advanced Breast Tumor Board: Pilot Application Cocreation and Implementation Study
- PMID: 37200077
- PMCID: PMC10236276
- DOI: 10.2196/39072
A Digital Solution for an Advanced Breast Tumor Board: Pilot Application Cocreation and Implementation Study
Abstract
Background: Cancer treatment is constantly evolving toward a more personalized approach based on clinical features, imaging, and genomic pathology information. To ensure the best care for patients, multidisciplinary teams (MDTs) meet regularly to review cases. Notwithstanding, the conduction of MDT meetings is challenged by medical time restrictions, the unavailability of critical MDT members, and the additional administrative work required. These issues may result in members missing information during MDT meetings and postponed treatment. To explore and facilitate improved approaches for MDT meetings in France, using advanced breast cancers (ABCs) as a model, Centre Léon Bérard (CLB) and ROCHE Diagnostics cocreated an MDT application prototype based on structured data.
Objective: In this paper, we want to describe how an application prototype was implemented for ABC MDT meetings at CLB to support clinical decisions.
Methods: Prior to the initiation of cocreation activities, an organizational audit of ABC MDT meetings identified the following four key phases for the MDT: the instigation, preparation, execution, and follow-up phases. For each phase, challenges and opportunities were identified that informed the new cocreation activities. The MDT application prototype became software that integrated structured data from medical files for the visualization of the neoplastic history of a patient. The digital solution was assessed via a before-and-after audit and a survey questionnaire that was administered to health care professionals involved in the MDT.
Results: The ABC MDT meeting audit was carried out during 3 MDT meetings, including 70 discussions of clinical cases before and 58 such discussions after the implementation of the MDT application prototype. We identified 33 pain points related to the preparation, execution, and follow-up phases. No issues were identified related to the instigation phase. Difficulties were grouped as follows: process challenges (n=18), technological limitations (n=9), and the lack of available resources (n=6). The preparation of MDT meetings was the phase in which the most issues (n=16) were seen. A repeat audit, which was undertaken after the implementation of the MDT application, demonstrated that (1) the discussion times per case remained comparable (2 min and 22 s vs 2 min and 14 s), (2) the capture of MDT decisions improved (all cases included a therapeutic proposal), (3) there was no postponement of treatment decisions, and (4) the mean confidence of medical oncologists in decision-making increased.
Conclusions: The introduction of the MDT application prototype at CLB to support the ABC MDT seemed to improve the quality of and confidence in clinical decisions. The integration of an MDT application with the local electronic medical record and the utilization of structured data conforming to international terminologies could enable a national network of MDTs to support sustained improvements to patient care.
Keywords: advanced breast cancer; breast cancer; cancer; care; clinician; confidence; data; digital health; electronic medical records; follow-up; genomic; multidisciplinary meeting; neoplastic; pain; pathology; patient; records; software; treatment; tumor.
©Khalil Hodroj, David Pellegrin, Cindy Menard, Thomas Bachelot, Thierry Durand, Philippe Toussaint, Armelle Dufresne, Benoite Mery, Olivier Tredan, Thibaut Goulvent, Pierre Heudel. Originally published in JMIR Cancer (https://cancer.jmir.org), 18.05.2023.
Conflict of interest statement
Conflicts of Interest: None declared.
Figures
Similar articles
-
Process Re-Engineering and Data Integration Using Fast Healthcare Interoperability Resources for the Multidisciplinary Treatment of Lung Cancer.JMIR Cancer. 2025 May 5;11:e53887. doi: 10.2196/53887. JMIR Cancer. 2025. PMID: 40324329 Free PMC article.
-
Improving the effectiveness of multidisciplinary team meetings for patients with chronic diseases: a prospective observational study.Southampton (UK): NIHR Journals Library; 2014 Oct. Southampton (UK): NIHR Journals Library; 2014 Oct. PMID: 25642498 Free Books & Documents. Review.
-
"No decision about me without me" in the context of cancer multidisciplinary team meetings: a qualitative interview study.BMC Health Serv Res. 2014 Oct 24;14:488. doi: 10.1186/s12913-014-0488-2. BMC Health Serv Res. 2014. PMID: 25339192 Free PMC article.
-
Strategies to improve the efficiency and utility of multidisciplinary team meetings in urology cancer care: a survey study.BMC Health Serv Res. 2014 Sep 8;14:377. doi: 10.1186/1472-6963-14-377. BMC Health Serv Res. 2014. PMID: 25196248 Free PMC article.
-
Implementation of streamlining measures in selecting and prioritising complex cases for the cancer multidisciplinary team meeting: a mini review of the recent developments.Front Health Serv. 2024 Mar 12;4:1340320. doi: 10.3389/frhs.2024.1340320. eCollection 2024. Front Health Serv. 2024. PMID: 38533189 Free PMC article. Review.
Cited by
-
The Use of an Integrated Digital Tool to Improve the Efficiency of Multidisciplinary Tumor Boards-A Prospective Trial in Taiwan.Cancers (Basel). 2025 Jan 28;17(3):444. doi: 10.3390/cancers17030444. Cancers (Basel). 2025. PMID: 39941815 Free PMC article.
-
Mixed Reality as a Digital Visualisation Solution for the Head and Neck Tumour Board: Application Creation and Implementation Study.Cancers (Basel). 2024 Mar 31;16(7):1392. doi: 10.3390/cancers16071392. Cancers (Basel). 2024. PMID: 38611070 Free PMC article.
References
-
- Miricescu D, Totan A, Stanescu-Spinu II, Badoiu SC, Stefani C, Greabu M. PI3K/AKT/mTOR signaling pathway in breast cancer: From molecular landscape to clinical aspects. Int J Mol Sci. 2020 Dec 26;22(1):173. doi: 10.3390/ijms22010173. https://www.mdpi.com/resolver?pii=ijms22010173 ijms22010173 - DOI - PMC - PubMed
-
- Braal CL, Jongbloed EM, Wilting SM, Mathijssen RHJ, Koolen SLW, Jager A. Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: Similarities and differences. Drugs. 2021 Feb;81(3):317–331. doi: 10.1007/s40265-020-01461-2. https://europepmc.org/abstract/MED/33369721 10.1007/s40265-020-01461-2 - DOI - PMC - PubMed
-
- Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, Zhang QY, Rodriguez JLM, Campone M, Hamilton E, Sohn J, Guarneri V, Okada M, Boyle F, Neven P, Cortés J, Huober J, Wardley A, Tolaney SM, Cicin I, Smith IC, Frenzel M, Headley D, Wei R, San Antonio B, Hulstijn M, Cox J, O'Shaughnessy J, Rastogi P, monarchE Committee Members and Investigators Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE) J Clin Oncol. 2020 Dec 01;38(34):3987–3998. doi: 10.1200/JCO.20.02514. https://europepmc.org/abstract/MED/32954927 - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources